TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23764566

Group type: EXPERIMENTAL
Intervention: MMT + AA (methadone maintenance treatment plus auricular acupuncture)
Number of subjects: 69

Group type: COMPARATOR
Intervention: MMT (methadone maintenance treatment)
Number of subjects: 69
Study: 21811051

Group type: EXPERIMENTAL
Intervention: 600 mg α‐lipoic acid (ALA) per day
Number of subjects: 467

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 467
Study: 18596668

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 117
Study: 16926119

Group type: EXPERIMENTAL
Intervention: mini‐BCP supplemented with potassium (initial/others: 15.4/9.8 mEq/L) and magnesium (initial/others: 6.5/4.0 mEq/L)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4:1‐diluted BCP modified with Buckberg solution
Number of subjects: 30
Study: 16306500

Group type: EXPERIMENTAL
Intervention: Squash specific graded test (ST)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Incremental treadmill test (TT)
Number of subjects: 7
Study: 11887513

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT + Surefil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT + Dyract Flow + Surefil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT + Flow-it + Surefil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT + Dyract AP + Surefil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fuji II LC + Prime & Bond NT + Surefil
Number of subjects: 20
Study: 10449027

Group type: EXPERIMENTAL
Intervention: Single-leg Wingate Test (SLWAnT) with constant braking force
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-leg Wingate Test (SLWAnT) with varying braking force
Number of subjects: 20
Study: 7598243

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: perphenazine 5 mg
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: metoclopramide 10 mg
Number of subjects: 360

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 360
Study: 1964885

Group type: EXPERIMENTAL
Intervention: NET-OEN (50 mg) + E2 valerate (5 mg) given every month
Number of subjects: 849

Group type: COMPARATOR
Intervention: NET-OEN (200 mg) given every 2 months
Number of subjects: 849
Study: 155389

Group type: EXPERIMENTAL
Intervention: Tryptophan-nicotinamide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tryptophan-nicotinamide-imipramine combination
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study: 31485282

Group type: EXPERIMENTAL
Intervention: Auto-CPAP
Number of subjects: 269

Group type: COMPARATOR
Intervention: Fixed-CPAP
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: CPAP level
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Oronasal masks
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Tobacco consumption
Number of subjects: 269
Study: 28417153

Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Open abdominal sacrocolpopexy
Number of subjects: 74
Study: 26473975

Group type: EXPERIMENTAL
Intervention: Regular intake of carotenoids from supplements and medications in amounts > 6.8 mg/d (upper tertile)
Number of subjects: 4447

Group type: COMPARATOR
Intervention: No intake of carotenoids
Number of subjects: 4447
Study: 23647889

Group type: EXPERIMENTAL
Intervention: Yoga intervention for 1 hour daily for 3 months along with oral hypoglycemic drugs
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral hypoglycemic drugs
Number of subjects: 100
Study: 21138361

Group type: EXPERIMENTAL
Intervention: 100% grape juice made from Concord grapes
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 85
Study: 18534438

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once daily
Number of subjects: 1896

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg once daily
Number of subjects: 1896

Group type: COMPARATOR
Intervention: Enoxaparin 30 mg SC BID
Number of subjects: 1896
Study: 16887327

Group type: EXPERIMENTAL
Intervention: Drospirenone containing oral contraceptive pill (Yasmin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15083986

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (beclomethasone metered-dose inhaler, tapering 4-week course)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Systemic corticosteroids (7-day course)
Number of subjects: 11
Study: 11454107

Group type: EXPERIMENTAL
Intervention: Prompted voiding (PV) during nighttime
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Daytime prompted voiding (PV)
Number of subjects: 61
Study: 9496526

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg intravenously
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg intravenously
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg intravenously
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (45 healthy men)
Number of subjects: 124
Study: 8049632

Group type: EXPERIMENTAL
Intervention: Cigarette smoking at the time of diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amount of cigarettes smoked per day and cumulative exposure (pack-years of use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking at the time of diagnosis, high pack-years of use, and smoking at the time of menarche
Number of subjects: 0
Study: 2647270

Group type: EXPERIMENTAL
Intervention: desipramine (150 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 31320350

Group type: EXPERIMENTAL
Intervention: Smell and taste of milk with each tube feed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tube feeding without the provision of smell and taste
Number of subjects: 0
Study: 30159779

Group type: EXPERIMENTAL
Intervention: DC vaccine (DCV)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 43
Study: 27015544

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 2.5 ppm DEX
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 5.0 ppm DEX
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 7.5 ppm DEX
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1% lidocaine with 1:80,000 AD
Number of subjects: 18
Study: 25408735

Group type: EXPERIMENTAL
Intervention: Clarithromycin (2×500 mg) + Amoxicillin (2×1 gr) + Omeprazole (2×20 mg) for 14 days
Number of subjects: 78

Group type: COMPARATOR
Intervention: Azithromycin (1×250 mg) + Amoxicillin (2×1 gr) + Omeprazole (2×20 mg) for 10 days
Number of subjects: 78
Study: 21978087

Group type: EXPERIMENTAL
Intervention: Music therapy in addition to routine nursing care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 120
Study: 20808794

Group type: COMPARATOR
Intervention: Industry funded RCTs
Number of subjects: 188

Group type: COMPARATOR
Intervention: Non-profit and mixed funding RCTs
Number of subjects: 188

Group type: COMPARATOR
Intervention: Any actual costs included
Number of subjects: 188

Group type: COMPARATOR
Intervention: Any mention of costs
Number of subjects: 188

Group type: COMPARATOR
Intervention: Any actual costs or mention of costs
Number of subjects: 188
Study: 17698978

Group type: EXPERIMENTAL
Intervention: Individualized herbal treatment from qualified herbal practitioners (n = 15), six consultations over 5 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n = 30) offered treatment after waiting 4 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Individualized herbal treatment
Number of subjects: 45
Study: 15618072

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12375708

Group type: EXPERIMENTAL
Intervention: Education group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Education group (compliant patients)
Number of subjects: 72
Study: 9932956

Group type: EXPERIMENTAL
Intervention: High dose interferon beta-1b (8.0 mIU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dose interferon beta-1b (1.6 mIU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7586436

Group type: EXPERIMENTAL
Intervention: Preoperative steroid (Solumedrol 250 mg IV, n = 16)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No steroid (n = 9, control group)
Number of subjects: 25
Study: 2310577

Group type: EXPERIMENTAL
Intervention: Caudal analgesia with bupivacaine (three different dosage regimens)
Number of subjects: 0
Study: 400045

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 29
Study: 31540980

Group type: EXPERIMENTAL
Intervention: Lifastuzumab vedotin (LIFA) at 2.4 mg/kg once every 3 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Lifastuzumab vedotin (LIFA) at doses ≥1.8 mg/kg
Number of subjects: 87
Study: 30722014

Group type: EXPERIMENTAL
Intervention: 15 g milk protein concentrate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 30 g milk protein concentrate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 45 g milk protein concentrate
Number of subjects: 48
Study: 29518135

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF test (post-Xpert group)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Conventional diagnostic tests (pre-Xpert group)
Number of subjects: 620
Study: 26454537

Group type: EXPERIMENTAL
Intervention: Increased end-diastolic wall stress
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Increased end-systolic wall stress
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Normal end-systolic wall stress <18 kPa
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Reduced PFR
Number of subjects: 1050
Study: 24968645

Group type: EXPERIMENTAL
Intervention: Twin-Force Bite Corrector (TFBC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Activator
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control Group (untreated)
Number of subjects: 10
Study: 22326504

Group type: EXPERIMENTAL
Intervention: 0.75 mg atrasentan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.75 mg atrasentan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.75 mg atrasentan (Hispanic subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.75 mg atrasentan (non-Hispanic subjects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum doses of RAS inhibitors
Number of subjects: 0
Study: 20191466

Group type: EXPERIMENTAL
Intervention: Communication about medication costs during visits
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Patient characteristics (white race, income $20,000-$59,999)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Physician characteristics (white race)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Medication changes
Number of subjects: 193
Study: 17412530

Group type: EXPERIMENTAL
Intervention: 1MIRP (4 weekly individual sessions of motivational interviewing and relapse prevention over 1 month)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 3MIRP (4 weekly individual sessions of motivational interviewing and relapse prevention over 3 months)
Number of subjects: 160

Group type: COMPARATOR
Intervention: DTC (Delayed Treatment Control)
Number of subjects: 160
Study: 17722316

Group type: EXPERIMENTAL
Intervention: 800 microg intravaginal misoprostol
Number of subjects: 50

Group type: COMPARATOR
Intervention: 400 microg intravaginal misoprostol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 12154111

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (3 ng/kg per minute for 45 minutes) and captopril during low salt balance
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High salt intake (200 mmol/d)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low salt intake (10 mmol/d)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Plasma renin activity
Number of subjects: 41
Study: 10834508

Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT) from related donors
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT) from unrelated donors
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Autologous stem-cell transplantation (SCT)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT) beyond the first CR
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (SCT) in the first CR
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Unrelated stem-cell grafting
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Autologous stem-cell grafting
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Myeloablative therapy followed by allogeneic stem-cell infusion
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Transplant-related mortality
Number of subjects: 118
Study: 8823101

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit (Duraflo II), n = 107
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group (uncoated circuit), n = 110
Number of subjects: 217
Study: 1454638

Group type: EXPERIMENTAL
Intervention: Abdominal radiographs interpreted by pediatric emergency physicians
Number of subjects: 126
Study: 2994148

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg every morning for 14 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30832742

Group type: EXPERIMENTAL
Intervention: IgGAM infusions for 5 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard-of-care treatment (SoC)
Number of subjects: 200
Study: 30212438

Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation intervention (QUIT) - 9-week program with 1 psychoeducation session and 9 weekly 1-hour sessions of cognitive behavioral therapy plus nicotine replacement therapy.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Enhanced standard smoking intervention (ETAU) - 9-week program with 1 psychoeducation session and 4 brief weekly check-in sessions plus nicotine replacement therapy.
Number of subjects: 72
Study: 27097348

Group type: EXPERIMENTAL
Intervention: PHiD‐CV + DTPa‐HBV‐IPV/Hib
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: PHiD‐CV + DTPa‐IPV‐Hib
Number of subjects: 774

Group type: COMPARATOR
Intervention: 7‐valent pneumococcal conjugate vaccine (7vCRM) + DTPa‐IPV‐Hib
Number of subjects: 774
Study: 25040965

Group type: EXPERIMENTAL
Intervention: Phone call
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Registered letter
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Postal letter
Number of subjects: 1000
Study: 22417026

Group type: EXPERIMENTAL
Intervention: Ketofol (1 mg/kg; 0.5 mg/kg propofol plus 0.5 mg/kg ketamine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propofol (1 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 24
Study: 20375405

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg) and Vitamin E (400 IU) supplementation
Number of subjects: 10154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10154
Study: 18422960

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha2a plus ribavirin
Number of subjects: 183

Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha2b plus ribavirin
Number of subjects: 183
Study: 16002175

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 3700
Study: 12640474

Group type: COMPARATOR
Intervention: Albendazole + placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivermectin + placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diethylcarbamazine + placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole + ivermectin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole + diethylcarbamazine
Number of subjects: 0
Study: 10843434

Group type: EXPERIMENTAL
Intervention: Inhaled steroid (budesonide) for 6 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Inhaled beta2‐agonist (terbutaline) for 6 weeks followed by inhaled steroid for 2 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 80
Study: 8704117

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Acute metabolic acidosis
Number of subjects: 8
Study: 1636162

Group type: EXPERIMENTAL
Intervention: High‐purity pasteurized FVIII concentrate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intermediate purity pasteurized FVIII concentrate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 8
Study: 29999185

Group type: EXPERIMENTAL
Intervention: Group-based ACT (ACTivate Your Life after Stroke)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 53
Study: 28953631

Group type: EXPERIMENTAL
Intervention: TPVBRA with 20 mL 0.25% bupivacaine + 1 μg/kg dexmedetomidine
Number of subjects: 72

Group type: COMPARATOR
Intervention: TPVBRA with 20 mL 0.25% bupivacaine
Number of subjects: 72
Study: 25955980

Group type: EXPERIMENTAL
Intervention: 1.5% Topical Diclofenac
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23369038

Group type: EXPERIMENTAL
Intervention: Paracetamol 1,000 mg sustained release (SR) tablets
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional paracetamol 500 mg tablets
Number of subjects: 500
Study: 21208923

Group type: EXPERIMENTAL
Intervention: Heterotypic vaccine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19353315

Group type: EXPERIMENTAL
Intervention: Biological dressing (Xenoderm)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 118
Study: 17535594

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 19
Study: 15161118

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-6 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Aspirin plus nimodipine
Number of subjects: 32
Study: 11465702

Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation (TLI)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Disease-Modifying Antirheumatic Drugs (DMARDs)
Number of subjects: 53
Study: 9570492

Group type: EXPERIMENTAL
Intervention: Antidepressants treatment for 5 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-responders to antidepressants
Number of subjects: 0
Study: 8068589

Group type: EXPERIMENTAL
Intervention: Patient controlled infusion of midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion of midazolam
Number of subjects: 0
Study: 3059852

Group type: EXPERIMENTAL
Intervention: 0.075 mg.kg‐1 midazolam intravenously 3 to 5 min prior to induction with fentanyl (5 micrograms.kg‐1.min‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31017079

Group type: EXPERIMENTAL
Intervention: E. coli samples
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: E. coli resistance profile
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: E. coli isolates
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: CTX‐M‐3 gene
Number of subjects: 314
Study: 28276901

Group type: EXPERIMENTAL
Intervention: HolisFiit®, a polyphenol-rich food supplement, daily supplementation for 16 weeks
Number of subjects: 0
Study: 25976046

Group type: EXPERIMENTAL
Intervention: Blood glucose levels of 4.4 to 6.1 mmol/L (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Blood glucose levels of 6.1 to 8.3 mmol/L (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Blood glucose levels of 8.3 to 10.0 mmol/L (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (non-septic subjects)
Number of subjects: 90
Study: 24079465

Group type: EXPERIMENTAL
Intervention: Presence of vertebral fractures in women
Number of subjects: 2887

Group type: EXPERIMENTAL
Intervention: Increasing numbers and severity of fractures in women
Number of subjects: 2887
Study: 21892418

Group type: EXPERIMENTAL
Intervention: Problem-solving treatment (PST)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 202
Study: 18836440

Group type: EXPERIMENTAL
Intervention: Selective serotonin or norepinephrine re‐uptake inhibitors after training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17413648

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 14687148

Group type: EXPERIMENTAL
Intervention: CDAI remission (CDAI < 150) at week 54
Number of subjects: 573

Group type: COMPARATOR
Intervention: Percentage of time in CDAI remission
Number of subjects: 573
Study: 11246736

Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study: 9015065

Group type: EXPERIMENTAL
Intervention: 0.2 mmol Gd/kg gadoxetic acid disodium
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.35 mmol Gd/kg gadoxetic acid disodium
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.5 mmol Gd/kg gadoxetic acid disodium
Number of subjects: 15
Study: 7957836

Group type: EXPERIMENTAL
Intervention: Nebulized frusemide (40 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 3602414

Group type: EXPERIMENTAL
Intervention: Amineptine treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31230500

Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure (LAAC) with the Watchman device
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Nonwarfarin oral anticoagulants (NOACs)
Number of subjects: 10000